Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × dalpiciclib × 90 days × Clear all

Phase

Status

Recruiting 4 Not yet recruiting 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Interviews as Topic 3 Educational Status 3 Standard of Care 2 Specimen Handling 2 Oxaliplatin 2 Methods 2 Leucovorin 2 Letrozole 2 Fluorouracil 2 Early Intervention, Educational 2 Cisplatin 2 Chemoradiotherapy 2 Biopsy 2 130-nm albumin-bound paclitaxel 2 zilucoplan 1 zanidatamab 1 trilaciclib 1 trastuzumab deruxtecan 1 tislelizumab 1 sitravatinib 1 sacituzumab govitecan 1 rozanolixizumab 1 pamiparib 1 olverembatinib 1 nimotuzumab 1 lenvatinib 1 futibatinib 1 exemestane 1 durvalumab 1 dalpiciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06650748 2026-03-17

NeoMARS

Peking University

Phase 2 Enrolling by invitation

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡